Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)
Study Details
Study Description
Brief Summary
The primary objective of this Expanded Access Program is to provide idebenone as a treatment for eligible participants with Duchenne Muscular Dystrophy before it is commercially available in the United States (U.S.) for the indication of DMD.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Documented diagnosis of DMD (severe dystrophinopathy) and clinical features consistent of typical DMD at diagnosis (i.e., documented delayed motor skills and muscle weakness by age 5 years) and who in the opinion of the Treating physician would benefit from treatment with idebenone. DMD should be confirmed by mutation analysis in the dystrophin gene or by substantially reduced levels of dystrophin protein (i.e., absent or <5% of normal) on Western blot or immunostaining.
-
Minimum 8 years old at Prescreening.
-
PEF or FVC ≤80% and >25% of predicted value based on most recent assessment noted in the patient's medical record and subsequently confirmed at the Enrollment Visit.
-
Able to understand program requirements and swallow program medication.
-
Signed and dated Informed Consent Form (to be obtained at the Enrollment Visit from patient or parent/legal guardian (if applicable) prior to performing any program-specific procedures and dispensing idebenone to the patient).
Exclusion Criteria:
-
Eligible for and able to participate in an ongoing clinical trial of idebenone.
-
Is at high-risk of a fatal outcome from lung infection and/or advanced cardiomyopathy in the opinion of the Treating physician.
-
Known moderate or severe impairment of hepatic function or severe impairment of renal function.
-
Prior or ongoing medical condition or laboratory abnormality which in the Treating physician's opinion may put the patient at significant risk or may interfere significantly with the patient's participation in the program.
-
Abuse of drugs or alcohol, which in Treating physician's opinion would interfere with the compliance to treatment.
-
Known individual hypersensitivity to idebenone or to any of the ingredients/excipients of the program medication.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Phoenix Children's Hospital | Phoenix | Arizona | United States | 85016 |
| 2 | Yale New Haven Hospital | New Haven | Connecticut | United States | 06510 |
| 3 | Lurie Children's Hospital of Chicago | Chicago | Illinois | United States | 60611 |
| 4 | University of Iowa | Iowa City | Iowa | United States | 52242 |
| 5 | University of Kansas Medical Center | Kansas City | Kansas | United States | 66160 |
| 6 | Kennedy Krieger | Baltimore | Maryland | United States | 21287 |
| 7 | Columbia University Pediatric Neuromuscular Center | New York | New York | United States | 10032 |
| 8 | Carolina's Healthcare System | Charlotte | North Carolina | United States | 28207 |
| 9 | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | United States | 45229 |
| 10 | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | United States | 19104 |
| 11 | University of Virginia Children's Hospital | Charlottesville | Virginia | United States | 22904 |
| 12 | St. Luke's Rehabilitation Institute | Spokane | Washington | United States | 99202 |
Sponsors and Collaborators
- Santhera Pharmaceuticals
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SNT-EAP-002